News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh
Previously, the use of the drug was limited to patients requiring hospitalization
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Go-ahead for pivotal clinical trial which is expected to commence by March
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Subscribe To Our Newsletter & Stay Updated
